Heterocyclic Compounds

Matches 151 - 200 out of 9,413	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2022/221227A9	AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing canc...
WO/2023/227139A1	FUSED PYRIMIDINE DERIVATIVE AND APPLICATION THEREOF The invention relates to a novel fused pyrimidine compound as shown in general formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and preparation methods and uses therefor. The meanings of R1, R2,...
WO/2023/226630A1	POLYMORPH OF KRAS INHIBITOR OR SALT THEREOF AND PREPARATION OF FORMULATION OF POLYMORPH Provided is a polymorph of a cycloalkyl and heterocycloalkyl inhibitor or a salt thereof. Specifically, the present invention relates to a polymorph of (S)-2-(4-(7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(1-((dimeth ylamino)methyl)cycloprop...
WO/2023/227052A1	BICYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF Disclosed herein are a compound represented by formula (II) or a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated form thereof, or a pharmaceutical composition comprising same, and use thereof as ...
WO/2023/230190A1	PYRIMIDINE BASED MODULATORS AND USES THEREOF Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.
WO/2023/223925A1	PHENOLIC HYDROXY GROUP-CONTAINING COMPOUND, CURABLE RESIN COMPOSITION, CURED PRODUCT, AND LAMINATE The present invention provides: a compound that, while being a curable resin, can easily achieve, when being formed into a cured product, the abilities to be repaired, to be easily disassembled, and to be remolded; and a curable resin co...
WO/2023/225302A1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
WO/2023/225244A1	HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
WO/2023/221797A1	HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, and a preparation method for the heterocyclic compound, and further relates to a use of the compound in the preparation of a drug for...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/215991A1	DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF Provided are compounds and method for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat disease, including, but not limited to, cancer. In certain emb...
WO/2023/220640A1	CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Provided herein are CDK protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CDK-me...
WO/2023/220098A1	MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCER The present disclosure is directed to methods of treating colorectal cancer in a subject in need thereof with a menin-MLL inhibitor, including Compound A. Methods for dosing Compound A for various indications are also provided by the pre...
WO/2023/220421A1	INHIBITORS OF KRAS(G12D) Provided are small molecule inhibitors of the KRAS (G12D) mutant oncoprotein having the structural formula: R00F2C-L-R0 and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related con...
WO/2022/213204A9	CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER The use of inhibitors of tyrosine and threonine- specific cdc2-inhibitory kinase (Mytl) in the treatment of cancer is disclosed. In preferred embodiments, the Mytl inhibitor is a carboxamide pyrrolopyrazine or carboxamide pyrrolopyridine...
WO/2023/220219A1	COMPOUNDS AND USES THEREOF The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
WO/2023/215494A1	THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
WO/2023/215906A1	KRAS G12D PROTEOLYSIS TARGETING CHIMERAS Provided herein are KRAS G12D proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS G12D PROTACs, and methods of making and using the KRAS G12D PROTACs, e.g., to promote degradation of KRAS G12D and/or treat KRAS G12...
WO/2023/215802A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
WO/2023/213882A1	IRREVERSIBLE MUTEGFR INHIBITORS Compounds of formula (I) processes for their production and their use as pharmaceuticals.
WO/2023/215801A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same in the treatment of cancer or for inhibiting cell growth. The compounds and methods have a range of utilities as thera...
WO/2023/212239A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds of formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
WO/2023/212535A1	FGFR2 INHIBITOR COMPOUNDS The present invention provides compounds of the formula (I):, or a pharmaceutically acceptable salt thereof, wherein A, X1, X2, X3, Y, Z, Z1, Z2, R2 and R6 are as defined herein, for use in the treatment of cancer and a method of treatin...
WO/2023/210741A1	BENZOTRIAZOLE COMPOUND The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
WO/2023/212071A1	COMBINATION AND THE USE THEREOF Provided here is a method of treating a cancer in a subject in need thereof, comprising administering to said subject a combination comprising: (i) about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg,...
WO/2023/210740A1	BENZOTHIOPHENE COMPOUND The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
WO/2023/207944A1	CRYSTAL FORM OF FGFR4 INHIBITOR AND USE THEREOF The present invention relates to a crystal form of an FGFR4 inhibitor and use thereof. The present invention provides a compound of formula B in crystalline form. The compound of formula B of the present invention has excellent FGFR4 kin...
WO/2023/208127A1	HETEROARYL-SUBSTITUTED BICYCLIC COMPOUND AND USE THEREOF Disclosed are a series of heteroaryl-substituted bicyclic compounds and use thereof, and particularly, disclosed are a compound represented by formula (P), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
WO/2023/210192A1	COMPOUND, LIGHT-EMITTING MATERIAL, AND ORGANIC LIGHT-EMITTING DEVICE This compound, represented by a general formula, is useful in a light-emitting device. Ar1 is a benzene ring, a naphthalene ring, a phenanthrene ring, or the like; D is a 5H-benzofuro[3,2-c]carbazol-5-yl group, or the like; A is a cyano ...
WO/2023/207992A1	INDOLE DERIVATIVE, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE The present invention relates to an indole derivative, an organic electroluminescent element, a display device, and a lighting device. The indole derivative of the present invention has a relatively high triplet level and a high glass tr...
WO/2023/207911A1	BICYCLIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION Disclosed are a bicyclic heterocyclic compound, a pharmaceutical composition and an application. Specifically, a compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharma...
WO/2023/205701A1	MACROCYCLIC HETEROCYCLES AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
WO/2023/205653A1	BICYCLIC COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2023/201780A1	METHOD FOR PREPARING QUINOLONE COMPOUND AND INTERMEDIATE THEREOF Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
WO/2023/202383A1	TETRAHYDROTHIENOPYRIDINE DEUTERATED DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF Disclosed in the present invention are a tetrahydrothienopyridine deuterated derivative, a preparation method therefor, and pharmaceutical use thereof. The derivative can be used for preparing a medicament for the prevention or treatment...
WO/2023/202531A1	CARBAZOLE DERIVATIVE, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE The present invention relates to a carbazole derivative, a luminescent material, a luminescent element, a display device, and a lighting device. The carbazole derivative of the present invention has a relatively high triplet energy level...
WO/2023/274324A9	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF Disclosed in the present invention are a nitrogen-containing heterocyclic compound, and a preparation method therefor, an intermediate thereof, and an application thereof. The present invention provides a nitrogen-containing heterocyclic...
WO/2023/202501A1	SUBSTITUTED PYRIDOPYRIMIDINONE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF A substituted pyridopyrimidinone compound, a composition comprising same, and use thereof. The compound is a compound represented by formula (I) or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt...
WO/2023/205251A1	COMPOUNDS ACTIVE TOWARDS BROMODOMAINS Disclosed are compounds of formula (I) which modulate bromodomains, pharmaceutical compositions containing said compounds and use of said compounds in therapy.
WO/2023/205463A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/203201A1	SUPRAMOLECULAR COMPLEX OF A BIOMOLECULE The invention provides a ternary complex of a cucurbituril host, such as CB[8], with a first aryl guest and second aryl guest, wherein the first aryl guest is a group within a biomolecule, such as insulin, and the first and second aryl g...
WO/2023/205778A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/204308A1	OXAZEPINE DERIVATIVE The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has superior orexin type-2 receptor agonist activity.
WO/2023/199999A1	COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE This compound is represented by general formula (1). In general formula (1), CN represents a cyano group, D12 represents a group represented by general formula (1A), and R101-R104 each independently represent a group represented by gener...
WO/2023/198078A1	POLYCYCLIC COMPOUNDS AS KRAS G12D INHIBITORS The present invention provides compounds as KRAS G12D inhibitors. Specifically, the present invention provides compounds having a structure represented by formula (I), or optical isomers, pharmaceutically acceptable salts, prodrugs, deut...
WO/2023/197934A1	SOLID SALT FORM OF OPIOID RECEPTOR ANTAGONIST CONJUGATE, CRYSTAL FORM, PREPARATION METHOD THEREFOR, COMPOSITION, AND USE The present invention relates to the technical field of pharmaceutical crystals, and relates to a solid salt form of an opioid receptor antagonist conjugate, a crystal form, a preparation method therefor, a composition, and a use. Specif...
WO/2023/198191A1	SIX- AND SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION Disclosed are a six- and six-membered compound, a preparation method, a pharmaceutical composition, and an application. Provided is a six- and six-membered compound as represented by formula (I) or a pharmaceutically acceptable salt ther...
WO/2023/193759A1	HPK1 ANTAGONISTS AND USES THEREOF Described herein are HPK1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with HPK1.
WO/2023/193085A1	BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalen...
WO/2023/195529A1	URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...

Matches 151 - 200 out of 9,413	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >